An interventional study of Standardized Breast Ultrasound Screening in Breast Neoplasms and Early Detection of Cancer, sponsored by The First Affiliated Hospital with Nanjing Medical University. Recruiting at 2 sites in China. Open to female participants aged 65 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by The First Affiliated Hospital with Nanjing Medical University · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Breast Neoplasms by The First Affiliated Hospital with Nanjing Medical University — 39 open to participants now, 40 under way, none of them phase 3. Breast Neoplasms · The First Affiliated Hospital with Nanjing Medical University.
Among the 57 studies in Breast Neoplasms by The First Affiliated Hospital with Nanjing Medical University, this one has the largest planned enrollment of the 44 interventional ones that give a count, is one of 10 that started in 2026, is one of 15 with no phase, reaches primary completion later than 35 of the 39 other live ones, and was the 53rd registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →39 of the 57 studies in Breast Neoplasms by The First Affiliated Hospital with Nanjing Medical University are open now, in 1 country. Recruiting first, the newest first:
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–75 · Women only
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–70 · Women only
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–75 · Women only
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–65 · Women only
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–75 · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 65 Years to 80 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80,000 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 76 across the 44 interventional studies, 100 across the 13 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
The First Affiliated Hospital with Nanjing Medical University is the lead sponsor of 569 studies on the registry; 317 are open to participants now.
10 of the studies in Breast Neoplasms by The First Affiliated Hospital with Nanjing Medical University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07446452The First Affiliated Hospital with Nanjing Medical UniversityDisitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study | 2026-12-06 |
| NCT06543992The First Affiliated Hospital with Nanjing Medical UniversityEfficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Methotrexate in Breast Cancer With Leptomeningeal Metastasis | 2026-12-13 |
| NCT07113613The First Affiliated Hospital with Nanjing Medical UniversityProspective Study on Exemption of Tumor Bed Boost Radiotherapy for pCR Patients After Breast Conserving Surgery With Neoadjuvant Therapy | 2026-12-31 |
| NCT06706726The First Affiliated Hospital with Nanjing Medical UniversityTo Evaluate the Effectiveness and Safety of Single-port Robotic-assisted Subcutaneous Gland Resection Combined With Immediate Breast Reconstruction in Breast Cancer | 2026-12-31 |
| NCT06561646The First Affiliated Hospital with Nanjing Medical UniversityTo Evaluate the Effectiveness and Safety of the Single-port Robotic-assisted Breast Surgery in Breast Cancer | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 57 studies in Breast Neoplasms by The First Affiliated Hospital with Nanjing Medical University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multicenter, cluster randomized trial will evaluate whether community-based breast ultrasound screening improves the early detection of breast cancer in women aged 65 to 80 years, compared with routine health management. Approximately 80,000 women in Jiangsu Province, China, will be enrolled and followed for breast cancer outcomes.
This is a multicenter, open-label, cluster randomized controlled trial in Jiangsu Province, China. Approximately 80,000 women aged 65 to 80 years will be enrolled. Participating community health service stations will be assigned to either active breast ultrasound screening or routine health management. Women in the screening group will receive a standardized breast ultrasound examination, while those in the control group will receive no additional study-specific breast screening. The primary outcome is the difference between groups in the proportion of diagnosed breast cancers that are stage I or II during 24 months of follow-up. The study will also assess other screening-related and implementation outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to this group through their community health service station receive one standardized breast ultrasound examination performed by a qualified physician. Abnormal findings are managed according to routine clinical practice.
Diagnostic Test: Standardized Breast Ultrasound Screening
Participants receive conventional community health management and annual physical examination according to local routine practice, without study-specific breast ultrasound screening.
One standardized breast ultrasound examination performed and interpreted by a qualified physician, with further clinical evaluation of abnormal findings as appropriate.
Absolute difference in early-stage breast cancer diagnosis rate
The between-group absolute difference in the proportion of pathologically confirmed breast cancer cases diagnosed at stage I or II.
Time frame: 24 months after enrollment
Overall breast cancer detection rate
The proportion of participants diagnosed with breast cancer in each group during follow-up.
Time frame: 24 months
Late-stage breast cancer diagnosis rate
The proportion of participants diagnosed with stage III or IV breast cancer in each group.
Time frame: Up to 24 months after enrollment
Breast biopsy rate
The proportion of participants undergoing a breast biopsy in each group during follow-up.
Time frame: Up to 24 months after enrollment
Plan to share: No — Individual participant data will not be shared because there is currently no approved data sharing policy for this multicenter study. De-identified participant data will be managed in accordance with institutional regulations and applicable ethical and legal requirements.
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Sep 2029, 36 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 36 months is close to that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: start Jul 2026 → Sep 2026 and primary completion Jul 2029 → Sep 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The First Affiliated Hospital with Nanjing Medical University →